65,437 trials
Leukemia · Lymphoma · Myelodysplastic Syndromes
Primary: Incidence of Graft Rejection for Patients at Day 100 — 0 participants
Postherpetic Neuralgia
Primary: Change in Mean Pain (NRPS) From Baseline to Endpoint in Mean Pain — -1.9447; -1.9786; -1.6798; -1.6633 Points
COPD
Primary: Time (in Minutes) to Patient's Perception of Onset of Effect — 25.13; 26.05; 21.88; 25.88 Minutes
Mucositis · Graft-versus-host Disease
Primary: Incidence of Severe Mucositis — 25; 14 participants — p=0.06
Neoplasms, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 7.4; 8.5 months
Hyperlipidemia · Blood Pressure · Oxidative Stress
Primary: LDL — 19.67; 20.04; 5.33; 0 mg/dL
PAIN
Primary: Postoperatory Analgesia After Total Knee Arthroplasty Comparing Femoral and Sciatic-femoral Block — 2; 2.8; 1.5 units on a scale
Multiple Sclerosis
Primary: Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio…
Interstitial Cystitis · Painful Bladder Syndrome
Primary: Global Response Assessment (GRA) Responders at Week 11. — 19; 15 participants
Cardiovascular Diseases
Primary: Brachial Artery Reactivity % Flow Mediated Dilation (BAR %FMD) — 5.49; 3.39 % FMD after 6 weeks of treatment — p=0.04
Sickle Cell Disease
Primary: Safety as Measured by the Number of Participants With Adverse Events — 9 participants
Obesity
Primary: Correlation Between Actual Epidural Needle Depth (ND) and Estimated Epidural Depth (Est-D) — 0.905; 0.899 correlation coefficient — p=< 0.05
Diabetic Foot Ulcers
Primary: Change in Wound Area — -32.74; -33.08; -49.34; -34.27 percentage of average change in wound
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Averaged Postprandial Glucose in Response to a MMT Test — 0.16; -0.44; -1.10; 0.51 mmol/L
Ecchymosis
Primary: Assess Extent of Bruising — .617; .736 a ratio of pixels